Docetaxel-loaded liposomes: Preparation, pH sensitivity, Pharmacokinetics, and tissue distribution

Journal of Zhejiang University: Science B

Volumn 13, Issue 12, 2012, Pages 981-989

  Zhang, Hong ^a   Li, Rui Ying ^a   Lu, Xia ^a   Mou, Zhen Zhen ^a   Lin, Gui Mei ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Docetaxel loaded liposomes; pH sensitivity; Pharmacokinetics; Tissue distribution

Indexed keywords

DOCETAXEL; DUOPAFEI; GENERIC DRUG; LIPOSOME; NANOFILM; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; DISPERSION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RELEASE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MORPHOLOGICAL TRAIT; MOUSE; NONHUMAN; PARTICLE SIZE; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SPLEEN; SUSTAINED DRUG RELEASE; TISSUE DISTRIBUTION; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS; DELAYED-ACTION PREPARATIONS; DIFFUSION; HYDROGEN-ION CONCENTRATION; LIPOSOMES; METABOLIC CLEARANCE RATE; MICE; ORGAN SPECIFICITY; TAXOIDS; TISSUE DISTRIBUTION;

MUS;

EID: 84875703667     PISSN: 16731581     EISSN: 18621783     Source Type: Journal    
DOI: 10.1631/jzus.B1200098     Document Type: Article

References (36)

1. Baker, J.; Ajani, J.; Scotté, F.; Winther, D.; Martin, M.; Aapro, M.S.; von Minckwitz, G.; 2009. Docetaxel-related side effects and their management. Eur. J. Oncol. Nurs.; 13(1):49-59. [doi:10.1016/j.ejon.2008.10.003]
2. Bissery, M.C.; 1995. Preclinical pharmacology of docetaxel. Eur. J. Cancer, 31(S4):S1-S6. [doi:10.1016/0959-8049 (95)00357-O]
3. Chu, C.J.; Dijkstra, J.; Lai, M.Z.; Hong, K.; Szoka, F.C.; 1990. Efficiency of cytoplasmic delivery by pH-sensitive liposomes to cells in culture. Pharm. Res.; 7(8):824-834. [doi:10.1023/A:1015908831507] (Pubitemid 20332534)
4. Connor, J.; Huang, L.; 1985. Efficient cytoplasmic delivery of a fluorescent dye by pH-sensitive immunoliposomes. J. Cell Biol.; 101(2):582-589. [doi:10.1083/jcb.101.2.582] (Pubitemid 15239134)
5. Ducat, E.; Deprez, J.; Peulen, O.; Evrard, B.; Piel, G.; 2010. Cellular uptake of long-circulating pH sensitive liposomes: evaluation of the liposome and its encapsulated material penetration in cancer cells. Drug Discov. Today, 15(23-24):1083. [doi:10.1016/j.drudis.2010.09.362]
6. Engels, F.K.; Sparreboom, A.; Mathot, R.A.; Verweij, J.; 2005. Potential for improvement of docetaxel-based chemotherapy: a pharmacological review. Br. J. Cancer, 93(2):173-177. [doi:10.1038/sj.bjc.6602698] (Pubitemid 41133202)
7. Friedenberg, W.R.; Graham, D.; Greipp, P.; Blood, E.; Winston, R.D.; 2003. The treatment of multiple myeloma with docetaxel (an ECOG study). Leuk. Res.; 27(8):751-754. [doi:10.1016/S0145-2126(02)00344-2] (Pubitemid 36683264)
8. Gelmon, K.; 1994. The taxoids: paclitaxel and docetaxel. Lancet, 344(8932):1267-1272. [doi:10.1016/S0140-6736 (94)90754-4] (Pubitemid 24334685)
9. Grant, D.S.; Williams, T.L.; Zahaczewsky, M.; Dicker, A.P.; 2003. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int. J. Cancer, 104(1):121-129. [doi:10.1002/ijc.10907] (Pubitemid 36184155)
10. Hait, W.N.; Rublin, E.; Alli, E.; Goodin, S.; 2007. Tubulin targeting agents. Update on Cancer Therapeutics.; 2(1):1-18. [doi:10.1016/j.uct.2006.10. 001]. (Pubitemid 46963732)
11. Hanauske, A.R.; Depenbrock, H.; Shirvani, D.; Rastetter, J.; 1994. Effects of the microtubule-disturbing agents docetaxel (Taxotere®), vinblastine and vincristine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitro. Eur. J. Cancer, 30(11):1688-1694. [doi:10.1016/0959-8049(94)00338-6] (Pubitemid 24355489)
12. Herbst, R.S.; Khuri, F.R.; 2003. Mode of action of docetaxel-a basis for combination with novel anticancer agents. Cancer Treat. Rev.; 29(5):407-415. [doi:10.1016/S0305-7372(03)00097-5] (Pubitemid 37185107)
13. Hiraka, K.; Kanehisa, M.; Tamai, M.; Asayama, S.; Nagaoka, S.; Oyaizu, K.; Yuasa, M.; Kawakami, H.; 2008. Preparation of pH-sensitive liposomes retaining SOD mimic and their anticancer effect. Colloids Surf. B Biointerfaces, 67(1):54-58. [doi:10.1016/j.colsurfb.2008.07.014]
14. Immordino, M.L.; Brusa, P.; Arpicco, S.; Stella, B.; Dosio, F.; Catte, L.; 2003. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J. Control. Release, 91(3):417-429. [doi:10.1016/S0168-3659(03)00271-2] (Pubitemid 36980659)
15. Izquierdo, M.A.; García, M.; Pontón, J.L.; Martínez, M.; Valentí, V.; Navarro, M.; Gil, M.; Cardenal, F.; Mesía, R.; Pérez, X.; Salazar, R.; Germà-Lluch, J.R.; 2006. A phase I clinical and pharmacokinetic study of paclitaxel and docetaxel given in combination in patients with solid tumours. Eur. J. Cancer, 42(12):1789-1796. [doi:10.1016/j.ejca.2005.10.031] (Pubitemid 44177567)
16. Kale, A.A.; Torchilin, V.P.; 2010. Environment-responsive multifunctional liposomes. Methods Mol. Biol.; 605: 213-242. [doi:10.1007/978-1-60327-360-2-15]
17. Li, J.; Yu, H.; Li, S.; Wang, G.J.; 2010. Enhanced distribution and extended elimination of glycyrrhetinic acid in mice liver by mPEG-PLA modified (mPEGylated) liposome. J. Pharm. Biomed. Anal.; 51(5):1147-1153. [doi:10.1016/j. jpba.2009.11.005]
18. Lian, T.; Ho, R.J.; 2001. Trends and developments in liposome drug delivery systems. J. Pharm. Sci.; 90(6):667-680. [doi:10.1002/jps.1023] (Pubitemid 32530443)
19. Maurer, N.; Fenske, D.B.; Cullis, P.R.; 2001. Developments in liposomal drug delivery Systems. Expert. Opin. Biol. Ther.; 1(6):923-947. [doi:10.1517/14712598.1.6.923]
20. Muthu, M.S.; Singh, S.; 2009. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders. Nanomedicine, 4(1):105-118. [doi:10.2217/17435889.4.1.105]
21. Parveen, S.; Misra, R.; Sahoo, S.K.; 2012. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine, 8(2):147-166. [doi:10.1016/j. nano.2011.05.016]
22. Philippot, J.R.; Mutaftschiev, S.; Liautard. J.P.; 1985. Extemporaneous preparation of large unilamellar liposomes. Biochim. Biophys. Acta.; 821(1):79-84. [doi:10.1016/0005-2736(85)90156-7] (Pubitemid 16233568)
23. Posner, M.R, Lefebvre, J.L.; 2003. Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck. Br. J. Cancer, 88(1):11-17. [doi:10. 1038/sj.bjc.6600685] (Pubitemid 36241211)
24. Rowinsky, E.K.; 1997. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu. Rev. Med.; 48:353-374. [doi:10.1146/annurev. med.48.1.353]. (Pubitemid 27101837)
25. Sánchez, M.; Aranda, F.J.; Teruel, J.A.; Ortiz, A.; 2011. New pH-sensitive liposomes containing phosphatidylethanolamine and a bacterial dirhamnolipid. Chem. Phys. Lipids, 164(1):16-23. [doi:10.1016/j.chemphyslip.20 10.09.008]
26. Straubinger, R.M.; Düzgünes, N.; Papahadjopoulos, D.; 1985. pH-sensitive liposomes mediate cytoplasmic delivery of encapsulated macromolecules, FEBS Lett.; 179(1):148-154. [doi:10.1016/0014-5793(85)80210-6] (Pubitemid 15153269)
27. Torchilin, V.P.; 2005. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov.; 4(2):145-160. [doi:10.1038/nrd1632] (Pubitemid 40282557)
28. Torchilin, V.P.; Zhou, F.; Huang, L.; 1993. pH-sensitive liposomes. J. Liposome Res.; 3(2):201-255. [doi:10.3109/08982109309148213] (Pubitemid 23217418)
29. Torchilin, V.P.; Lukyanov, A.N.; Klibanov, A.L.; Omelyanenko, V.G.; 1992. Interaction between oleic acid-containing pH-sensitive and plain liposomes. Fluorescent spectroscopy studies. FEBS Lett.; 305(3):185-188. [doi:10. 1016/0014-5793(92)80663-2]
30. Tosi, G.; Vergoni, A.V.; Ruozi, B.; Bondioli, L.; Badiali, L.; Rivasi, F.; Costantino, L.; Forni, F.; Vandelli, M.A.; 2010. Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: in vivo pharmacological evidence and biodistribution. J. Control. Release, 145(1):49-57. [doi:10.1016/j.jconrel. 2010.03.008]
31. Vassilomanolakis, M.; Koumakis, G.; Barbounis, V.; Demiri, M.; Panopoulos, C.; Chrissohoou, M.; Apostolikas, N.; Efremidis, A.P.; 2005. First-line chemotherapy with docetaxel and cisplatin in metastatic breast cancer. Breast, 14(2):136-141. [doi:10.1016/j.breast.2004.08.017] (Pubitemid 40353041)
32. Yang, F.; Jin, C.; Jiang, Y.; Li, J.; Di, Y.; Ni, Q.; Fu, D.; 2011. Liposome based delivery systems in pancreatic cancer treatment: from bench to bedside. Cancer Treat. Rev.; 37(8):633-642. [doi:10.1016/j.ctrv.2011.01.006]
33. Yuba, E.; Kojima, C.; Harada, A.; Tana, Watarai, S.; Kono.; K.; 2010. pH-sensitive fusogenic polymer-modified liposomes as a carrierof antigenic proteins for activation of cellular immunity. Biomaterials, 31(5):943-951. [doi:10.1016/j.biomaterials.2009.10.006]
34. Zhang, P.; Ling, G.; Pan, X.; Sun, J.; Zhang, T.; Pu, X.; Yin, S.; He, Z.; 2012. Novel nanostructured lipid-dextran sulfate hybrid carriers overcome tumor multidrug resistance of mitoxantrone hydrochloride. Nanomedicine, 8(2):185-193. [doi:10.1016/j.nano.2011.06.007]
35. Zhao, L.; Wei, Y.M.; Zhong, X.D.; Liang, Y.; Zhang, X.M.; Li, W.; Li, B.B.; Wang, Y.; Yu, Y.; 2009. PK and tissue distribution of docetaxel in rabbits after i.v. administration of liposomal and injectable formulations. J. Pharm. Biomed. Anal.; 49(4):989-996. [doi:10.1016/j.jpba.2009.01.016]
36. Zignani, M.; Drummond, D.C.; Meyer, O.; Hong, K.; Leroux, J.C.; 2000. In vitro characterization of a novel polymeric-based pH-sensitive liposome system. Biochim. Biophs. Acta, 1463(2):383-394. [doi:10.1016/S0005-2736(99)00234-5] (Pubitemid 30081796)